UK – NICE recommends Roche’s Polivy for B-cell lymphoma

The UK’s National Institute for Health and and Care Excellence (NICE) has recommended the use of Roche’s antibody drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL).

According to NICE, around 4,800 people in England have DLBCL, with around 530 of those eligible for the new Polivy (polatuzumab vedotin) combination treatment. It will be made available from today for patients whose cancer has relapsed or not responded to primary treatment, and who are not eligible for stem cell transplant.

Earlier this year, NICE initially rejected the new cancer drug, citing a lack of long-term evidence as the reason for the rejection. NICE said that the cost-effectiveness of the Polivy combination treatment was ‘very uncertain’, meaning it couldn’t recommend the drug for use within NHS England or the Cancer Drugs Fund…